{"protocolSection":{"identificationModule":{"nctId":"NCT03549975","orgStudyIdInfo":{"id":"NRC-2016-02-011"},"organization":{"fullName":"National Rehabilitation Center, Seoul, Korea","class":"OTHER_GOV"},"briefTitle":"Hand Rehabilitation Using Botulinum Toxin and Functional Electrical Stimulation-pilot Study","officialTitle":"Hand Rehabilitation Using Botulinum Toxin and Functional Electrical Stimulation Among Stroke Patients With Limitation of Finger Extension Due to Spasticity- Pilot Study"},"statusModule":{"statusVerifiedDate":"2018-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-05-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-08-18","type":"ACTUAL"},"completionDateStruct":{"date":"2017-08-18","type":"ACTUAL"},"studyFirstSubmitDate":"2018-05-16","studyFirstSubmitQcDate":"2018-05-25","studyFirstPostDateStruct":{"date":"2018-06-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-05-25","lastUpdatePostDateStruct":{"date":"2018-06-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Joon-Ho Shin","investigatorTitle":"Team manager of Department of Neurorehabilitation","investigatorAffiliation":"National Rehabilitation Center, Seoul, Korea"},"leadSponsor":{"name":"National Rehabilitation Center, Seoul, Korea","class":"OTHER_GOV"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The investigator tried to find out possibility of functional improvement using botulinum toxin injection targeting finger flexor spasticity with functional electrical stimulation among chronic stroke patients who did not show any improvement in hand function."},"conditionsModule":{"conditions":["Stroke","Spastic Hemiparesis","Spasticity as Sequela of Stroke"],"keywords":["stroke","hand","botulinum toxin","functional electrical stimulation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":20,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Botulinum toxin type A injection","type":"EXPERIMENTAL","description":"Botulinum toxin type A injection followed by functional electrical stimulation","interventionNames":["Drug: Botulinum Toxin Type A 100 unit/Vial (Product)"]}],"interventions":[{"type":"DRUG","name":"Botulinum Toxin Type A 100 unit/Vial (Product)","description":"Botulinum toxin type A injection followed by functional electrical stimulation","armGroupLabels":["Botulinum toxin type A injection"],"otherNames":["functional electrical stimulation"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Box and Block test","description":"number of box moved by affected upper extremity","timeFrame":"baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline"},{"measure":"Change of Action Research Arm Test","description":"Score of Action Research Arm Test","timeFrame":"baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline"}],"secondaryOutcomes":[{"measure":"Muscle strength of finger extensor","description":"Medical research council grading of muscle strength","timeFrame":"baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline"},{"measure":"Spasticity of finger extensor","description":"Modified ashworth scale of finger flexor","timeFrame":"baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline"},{"measure":"active range of motion of wrist joint","description":"active range of motion of wrist joint","timeFrame":"baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline"},{"measure":"Brunnstrom stage of stroke recovery of distal upper extremity","description":"Brunnstrom stage of stroke recovery of distal upper extremity. By observing the pattern of participants posture, the stage was scored. The stage ranges from 1 to 6. Higher is better.","timeFrame":"baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline"},{"measure":"Distance from middle finger tip to mid-palmar crease","description":"Distance from middle finger tip to mid-palmar crease","timeFrame":"baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline"},{"measure":"Repeated number of finger extension and flexion","description":"Repeated number of finger extension and flexion","timeFrame":"baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline"},{"measure":"Quick Disabilities of Arm, Shoulder & Hand","description":"Quick Disabilities of Arm, Shoulder \\& Hand is questionnaire about patients' symptoms as well as ability to perform certain activities in the last week.\n\nTotal score is obtained by summing the each question, and ranges from 0 (no disability) to 100 (most severe disability).","timeFrame":"baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline"},{"measure":"Grading of active thumb opposition","description":"Grading of active thumb opposition. It is measured by observing the pattern of thumb opposition.","timeFrame":"baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline"},{"measure":"Grip strength","description":"measured by Jamar dynamometer","timeFrame":"baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline"},{"measure":"Active finger extension","description":"Active finger extension. It is graded by observation of voluntary finger extension.","timeFrame":"baseline, 2 weeks after baseline, 6 weeks after baseline, 10 weeks after baseline"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* age over 18 years\n* hemiplegic upper limb spasticity secondary to a unilateral ischemic or hemorrhagic stroke\n* fingers and wrist flexor spasticity graded at least 1+ on the Modified Ashworth Scale\n* at least 6 months since stroke\n\nExclusion Criteria:\n\n* fixed contracture\n* previous treatment of the upper limb spasticity with neurolytic or surgical procedure\n* treatment with botulinum toxin type A in the previous 4 months\n* any active device implant\n* any neurological disorder, other than stroke causing motor deficits or spasticity\n* inability to attend to and/or to cooperate with all outcome measure-related task secondary to cognitive impairment or aphasia\n* pregnancy, planned pregnancy, or lactation\n* contraindication to botulinum toxin type A","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Joon-Ho Shin, MS","affiliation":"National Rehabilitation Center of Korea","role":"PRINCIPAL_INVESTIGATOR"}]}},"annotationSection":{"annotationModule":{"unpostedAnnotation":{"unpostedResponsibleParty":"Joon-Ho Shin, Team manager of Department of Neurorehabilitation, National Rehabilitation Center, Seoul, Korea","unpostedEvents":[{"type":"RELEASE","date":"2019-03-11"},{"type":"RESET","date":"2019-06-13"}]}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"estimatedResultsFirstSubmitDate":"2019-03-11","submissionInfos":[{"releaseDate":"2019-03-11","resetDate":"2019-06-13"}]}},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000020521","term":"Stroke"},{"id":"D000010291","term":"Paresis"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M20634","name":"Muscle Weakness","relevance":"LOW"},{"id":"M12894","name":"Paresis","asFound":"Hemiparesis","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Previous","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Previous","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":false}